⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure 17 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy

Bartlomiej Borek Julita Nowicka Anna Gzik Marek Dzięgielewski Karol Jedrzejczak Joanna Brzezinska Marcin Grzybowski Paulina Stanczak Paulina Pomper Agnieszka Zagożdżon Tomasz Rejczak Krzysztof Matyszewski Adam Gołȩbiowski Jacek Olczak Kamil Lisiecki Magdalena Tyszkiewicz Magdalena Kania Sylwia Piasecka Anna Cabaj Paulina Dera Krzysztof Mulewski Jacek Chrzanowski Damian Kusmirek Elżbieta Sobolewska Marta Magdycz Lukasz Mucha Marek Masnyk Jakub Gołąb Marcin Nowotny Elżbieta Nowak Agnieszka Napiórkowska-Gromadzka Stanislaw Pikul Radosław Jaźwiec Karolina Dzwonek Pawel Dobrzanski Michael Meyring Krzysztof Skowronek Piotr Iwanowski Zbigniew Zasłona Roman Błaszczyk

View at Publisher

Ask AI

Bookmark

Share

Abstract

This is the authors' abstract. We don't add key points for this paper.

Analysis of B16F10 tumor growth in mice treated with OATD-02 in all individuals subjected to the study.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Borek et al. (2024) studied this question.

synapsesocial.com/papers/68e58589b6db643587522493 https://doi.org/10.1158/1535-7163.27035803

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 17 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy2024
2Supplementary Figure 16 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy2024
3Supplementary Figure 16 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy2024
4Supplementary Figure 18 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy2024
5Supplementary Figure 18 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy2024

Supplementary Figure 22 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy2024
Supplementary Figure 22 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy2024
Supplementary Figure 23 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy2024